Developments in neuroimaging: Positron emission tomography

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5 hydroxytryptamine (5HT, serotonin); 6 18F fluoro L dopa (F dopa); Acetylcholine; Alpha synuclein; Beta amyloid; Dopamine; Dopamine transporter (DAT); Microglia; Positron emission tomography; Vesicular monoamine transporter type 2 (VMAT2)

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BRAIN REGION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; HUMAN; IMAGE ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS DEVELOPMENT;

5-HYDROXYTRYPTAMINE (5HT, SEROTONIN); 6-[(18)F]FLUORO-L-DOPA (F-DOPA); ACETYLCHOLINE; ALPHA-SYNUCLEIN; BETA-AMYLOID; DOPAMINE; DOPAMINE TRANSPORTER (DAT); MICROGLIA; POSITRON EMISSION TOMOGRAPHY; VESICULAR MONOAMINE TRANSPORTER TYPE 2 (VMAT2);

BRAIN; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84887912227     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70042-7     Document Type: Article

References (30)

1. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010, 9:149-158.
2. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011, 69:803-810.
3. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136:2419-2431.
4. Sossi V, Fuente-Fernandez R, Nandhagopal R, Schulzer M, McKenzie J, Ruth TJ, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 2010, 25:2717-2723.
5. de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
6. de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001, 49:298-303.
7. Sossi V, Fuente-Fernandez R, Holden JE, Schulzer M, Ruth TJ, Stoessl J Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004, 24:869-876.
8. Carta M, Carlsson T, Kirik D, Bjorklund A Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
9. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010, 2:38ra46.
10. Piccini P, Weeks RA, Brooks DJ Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997, 42:720-726.
11. Van Laere K, Casteels C, Lunskens S, Goffin K, Grachev ID, Bormans G, et al. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol Aging 2012, 33:620-628.
12. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76:1811-1816.
13. Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73:1670-1676.
14. Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010, 133:1747-1754.
15. Kotagal V, Albin RL, Muller ML, Koeppe RA, Chervin RD, Frey KA, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 2012, 71:560-568.
16. 11C]DASB. Mov Disord 2008, 23:1776-1780.
17. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010, 75:1920-1927.
18. Joutsa J, Rinne JO, Eskola O, Kaasinen V Reduced striatal dopamine synthesis capacity is associated with symptoms of depression in patients with de novo unmedicated Parkinson's disease. J Parkinsons Dis 2013, 3:325-329.
19. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67:589-595.
20. Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD, Josephs KA, et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord 2011, 17:260-264.
21. 11C] raclopride PET study. Brain 2009, 132:1376-1385.
22. O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011, 134:969-978.
23. van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 2009, 34:2758-2766.
24. van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010, 75:1711-1716.
25. Kikuchi A, Takeda A, Okamura N, Tashiro M, Hasegawa T, Furumoto S, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010, 133:1772-1778.
26. Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, et al. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol 2009, 617:54-58.
27. Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, et al. Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One 2013, 8:e55031.
28. Donaghy P, Thomas AJ, O'Brien JT Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry 2013 Jul 3, [Epub ahead of print].
29. 11C]-PK11195 PET: quantification of neuroinflammation and a monitor of antiinflammatory treatment in Parkinson's disease?. Parkinsonism Relat Disord 2010, 16:57-59.
30. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012, 32:1-5.